Saskia de Groot completed the bachelor programme Health Policy & Management at the Erasmus University Rotterdam in 2007. In 2009, she obtained her master’s degree in Health Economics, Policy & Law. She continued her studies by enrolling in a research master programme in Health Sciences with a specialisation in Clinical Epidemiology at the Netherlands Institute for Health Sciences (2009–2011).
During her studies at the Erasmus University Rotterdam, she started working as a research assistant at the institute of Health Policy & Management. After obtaining her master's degree, she started working on a PhD project on the evaluation of clinical and economic outcomes of new therapies for metastatic renal cell carcinoma at the same institute. She finished her PhD thesis in 2016. Besides her research on conditional funding of expensive inpatient drugs, she worked on various advisory projects, including different projects for the Dutch National Health Care Institute.
B. Grigore, O. Ciani, F. Dams, C. Federici, S. de Groot, M. Möllenkamp, S. Rabbe, K. Shatrov, A. Zemplenyi & R. Taylor (2020). Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines. Pharmacoeconomics (Print), 38, 1055-1070. doi: 10.1007/s40273-020-00935-1
S. de Groot, W.K. Redekop, M.M. Versteegh, S. Sleijfer, E. Oosterwijk, L.A.L.M. Kiemeney & C.A. Uyl - de Groot (2018). Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma. Quality of Life Research, 27, 115-124. doi: 10.1007/s11136-017-1704-4